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Cerebral cavernous malformations are the most common vascular malformations and can be found in many locations in the brain.
If left untreated, cavernomas may lead to intracerebral hemorrhage, seizures, focal neurological deficits, or headaches. As they
are angiographically occult, their diagnosis relies on various MR imaging techniques, which detect different characteristics of the
lesions as well as aiding in planning the surgical treatment. The clinical presentation and the location of the lesion are the most
important factors involved in determining the optimal course of treatment of cavernomas. We concisely review the literature and
discuss the advantages and limitations of each of the three available methods of treatment—microsurgical resection, stereotactic
radiosurgery, and conservative management—depending on the lesion characteristics.
1. Introduction
Cerebral cavernous malformations (CMs), also known as
cavernomas, are vascular abnormalities of the brain that
are comprised of clusters of abnormal, hyalinized capillaries
surrounded by hemosiderin deposits and a gliotic margin [1–
3]. The vasculature is filled with blood and is thrombosed in
varying degrees.
The incidence of cerebral CMs ranges from 0.4% to 0.8%
in the general population, but they are the most common
vascular abnormality, making up 10–25% of all vascular
malformations. They can be found in several locations in
the brain, but 70–80% of them are supratentorial [1, 4].
Supratentorial CMs most frequently present with new-onset
seizures, but headaches are also common, while infratentorial
CMs usually lead to progressive neurological deficits [5, 6].
Intracranial hemorrhages of varying severity can also occur
in both supratentorial and infratentorial lesions. The annual
risk of hemorrhage is 0.7–1.1% per lesion in patients with no
history of hemorrhage but rises to 4.5% in patients with a
previous intracerebral hemorrhage (ICH) [7–10]. The risk of
rupture also depends on the location of the lesion, its size, the
presence of a developmental venous anomaly (DVA), and the
patient’s gender. Superficial CMs have a lower ICH risk than
the deeply located ones. More specifically, the ICH risk for
infratentorial CMs is 3.8% but 0.4% for supratentorial CMs
[9, 11]. Additionally, female patients have a worse prognosis
than male patients [12, 13].
Approximately 40–60% of patients with CMs have the
familial form, inherited in an autosomal dominant pattern
due to a heterozygous mutation in one of the three genes,
CCM1, CCM2, and CCM3, found on the 7q, 7p, and 3p
chromosomes, respectively [1]. The familial form usually
results in multiple cavernomas, whereas the sporadic disease
typically leads to a single cavernoma [14, 15]. The products of
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Figure 1: Flow-chart of the work-up and management of patients with cavernous malformations. Once a cavernomas is diagnosed via an
MRI of the brain, deciding the course of treatment depends on the clinical presentation of the patient. Purely incidental cavernomas are
managed conservatively and followed by yearly MRI scans. Cavernomas are treated by microsurgical resection or stereotactic radiosurgery if
the patient is experiencing severe symptoms, such as intractable seizures, progressive neurological deterioration, one severe hemorrhage in a
noneloquent region of the brain, or at least two severe hemorrhages in eloquent brain. Selecting between resection and radiosurgery depends
on the location of the lesion and the severity of the presentation as explained in this paper.
the CM genes have been shown to play a major role in angio-
genesis by associating with cytoskeletal and interendothelial
cell junction proteins in neural tissue [2]. Loss-of-function
mutations in one of these genes disrupt the endothelial cell-
cell junctions, leading to extensive vascular abnormalities and
increased permeability.
Microsurgical resection, stereotactic radiosurgery, and
conservativemanagement are the threemethods of treatment
for CM lesions. Deciding how to manage a CM patient
depends on a multitude of factors that are discussed in this
paper (Figure 1). While there are many studies on each of
these methods, the natural history of CM lesions is com-
plicated and not clearly understood, which may potentially
compromise the conclusions drawn regarding the efficacy
of the treatment used. Temporal clustering of hemorrhages
has been shown in patients with untreated CMs; a 2.4-
fold decrease (𝑃 < 0.001) in the rate of bleeding was
observed 2.5 years after the first hemorrhage [16]. Some
are more skeptical regarding temporal clustering due to
the absence of a second period of increased risk within 5
years of follow-up [17]. In that case, the risk of hemor-
rhage is naturally reduced 2 to 3 years after a hemorrhagic
event.
2. Clinical Imaging Used for CM Management
The diagnosis of cavernomas is more difficult than other
vascular diseases since CMs are angiographically occult mal-
formations. Angiography is only able to detect the existence
of abnormal venous drainage associated with CMs; thus
other imaging techniques are needed to provide an accurate
diagnosis. Conventional T1- and T2-weighted MR imag-
ing, gradient echo sequences, high-field MRI, susceptibility-
weighted imaging, diffusion tensor imaging, and functional
MRI are some of the advanced techniques that are being used
for diagnosis of CMs or for intraoperative navigation during
the treatment of deeply located lesions.
2.1. Conventional T1- and T2-WeightedMR Imaging. Conven-
tional MR imaging is able to accurately detect symptomatic
cavernous malformations, which are surrounded by a ring
of hypointensity due to hemosiderin deposits from recurring
microhemorrhages [7, 18]. The CM lesions are divided into
four types based on their appearance on MR imaging. Type I
lesions appear hyperintense on T1- and T2-weighted imaging
due to a hemosiderin core from subacute hemorrhage. Type
II lesions contain loculated hemorrhages enveloped by gliotic
tissue, presenting as a mixed signal on both T1 and T2
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sequences. On T2 imaging, type II lesions also have a hypo-
intense rim, resulting in the “popcorn” appearance [19]. Type
III lesions are diagnosed by the presence of an isointense
core, indicating chronic resolved hemorrhage, typically seen
in familial CM. Type IV lesions are small malformations
that can only be seen in gradient recalled echo (GRE)
MRI as hypointense foci and are thought to be capillary
telangiectasias [18, 20].
2.2. Gradient Recalled Echo (GRE) MR Imaging. GRE MR
imaging is a key method for diagnosis of CMs due to its
ability to display hemosiderin-filled brain tissue with a very
distinct hypointensity. Studies on familial CMs have shown
that conventional MR imaging detected an average of 5
lesions per patient, while T2-weighted GRE MRI identified
an average of 16 lesions per patient [21]. GRE MRI not only
is more capable of identifying all of the lesions present,
but also delineates the lesions more precisely [22]. While it
has several benefits, it is important to note that GRE MRI
augments the apparent size of the CM lesion. Additionally,
GRE MR images may show multifocal lesions in elderly
patients with hypertension and a history of stroke, but they
must not be mistaken for familial CMs. They result from
hypertensive angiopathy and are located in periventricular
areas [7].
2.3. Use of High-Field MRI for Diagnosis of CMs. The use
of conventional 1.5 T MR imaging is limited, as CM lesions
may not be visualized unless high-field MR imaging is used.
Using MR strengths of up to 14 Tesla, several studies have
illustrated the ability of high-field imaging to visualize lesions
as hypointensities that were not otherwise apparent [23–
25]. Depending on the strength, lesions may appear to be
larger than in reality. More specifically, high-field imaging at
7 T causes lesions to appear 11% larger than in conventional
imaging techniques [25].
2.4. Susceptibility-Weighted MR Imaging. Susceptibility-
weighted (SW) imaging is very advantageous for detect-
ing CM lesions because it accurately recognizes deoxy-
hemoglobin and hemosiderin. It is also considered the
only method capable of detecting unbled CM lesions and
telangiectasias [7]. SW imaging has been shown to delineate
CMs more precisely as well as detect additional CM lesions
that cannot be seen by conventional imaging methods. De
Souza et al. studied 15 patients with familial CMs and found
5.7, 26.3, and 45.6 lesions per patient using T2-weighted
imaging, T2 ∗ GRE imaging, and SW imaging, respectively.
SW imaging detected 1.7 times more lesions than T2 ∗
GRE (𝑃 = 0.001) [26]. Other studies on familial CMs
corroborate these findings; however, SW imaging is not
superior to T2 ∗ GRE imaging regarding the detection of
sporadic, solitary CMs or clusters of CMs associated with a
DVA [7]. Additionally, using sequential SW imaging with
contrast agent may prove very useful in distinguishing
venous vasculature from small regions of hemorrhage, but
this application of SW imaging needs to be studied further
[27].
2.5. Diffusion Tensor (DT) Imaging and fMRI Used Intraop-
eratively. DT and fMR imaging are used intraoperatively to
better visualize the lesions and the surrounding parenchyma
in order to improve the surgical outcome even if the lesions
are deeply located in eloquent areas. DT tractography allows
the surgeon to visualize the white matter tracts, which fre-
quently cross through the hemosiderin rim of the CM lesion
[19]. Several studies have shown the successful use of DT
imaging in locating the tracts and avoiding them, significantly
decreasing the morbidity associated with CM resections [28–
30]. fMR imaging measures activity-dependent changes in
cerebral blood flow, which becomes especially useful when
resecting CM lesions located in eloquent brain [31, 32]. Zotta
et al. show the use of fMRI for surgical planning and intra-
operative navigation and report higher rates of completely
seizure-free patients [33]. The use of fMRI neuronavigation
enabled them to follow a more aggressive approach on the
perilesional tissue without increasing the morbidity rate [33].
There is promising evidence supporting the use of DT
and fMR imaging intraoperatively to achieve better outcomes
without an increase in the morbidity and mortality rates.
However, most studies on the neuronavigation techniques
involve only a small number of patients; further investigation
of these techniques is warranted using a larger number of
patients to ensure generalizability.
3. Microsurgical Resection
Cavernous malformations are dynamic lesions that may
exhibit enlargement, regression, or even de novo formation
[3, 34].They are resected after patients have experiencedmul-
tiple hemorrhages in eloquent areas, or a single hemorrhage
in a noneloquent area that is associated with deteriorating
neurological deficits [35]. In addition, experiencing severe
symptoms, such as cardiac or respiratory instability, and the
presence of a CM lesion within 2mm from the pial surface
are important indications for surgery [5]. Patients are treated
with steroids for 1 to 2 weeks prior to the surgery in order
to limit the edema and allow for the CM resection. If there
is a DVA associated with the CM lesion, its resection should
be avoided because removing the DVA entails a high risk of
venous infarction [9]. Moreover, upon excision of the CM
lesion, gliosis, calcification, and hyaline degeneration often
take place and may complicate the procedure [5].
Complete removal of the lesion is required in order
to prevent recurring hemorrhagic events, but that depends
on the neurosurgeon’s experience [36]. Resection of the
hemosiderin ring must also be accomplished if seizure
surgery is performed. Rebleeding has been shown to occur
in 40% of cavernoma remnants after surgery, which is why a
postoperativeMRIwithin 72 hours is strongly recommended.
If remnants are found, surgical intervention is needed as early
as possible [37].
The complication risks associated with surgical interven-
tion vary with the location of the CM lesion. Amin-Hanjani
et al. showed that the patients’ overall neurological condition
was good or excellent in 100% of patients with cranial nerve
CMs, 97% of those with lobar CMs, 87.5% of those with
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cerebellar CMs, 75% of those with spinal cord CMs, and 64%
of those with brainstem CMs [38].
3.1. Supratentorial Cavernomas. The vast majority of CM
lesions are located supratentorially and most commonly
present with seizures, focal neurological disorders, and
headaches depending on their location. Surgical resection
of symptomatic CM lesions located in noneloquent areas is
always recommended, as it has been shown to be safe as
well as effective in treating epilepsy and preventing future
hemorrhages [4, 39]. However, deciding on whether to resect
a CM becomes more complicated when the lesion is located
in an eloquent area of the brain and is barely symptomatic
or completely asymptomatic. The use of frameless stereotaxy
and intraoperative fMR imaging significantly reduces the risk
of complications and establishes microsurgical resection as
a favorable treatment method for most supratentorial CM
lesions. Gralla et al. report complete removal of the CM lesion
using intraoperative navigation in all of the patients studied
[40].
Surgical resection of CM lesions has also been shown to
allow long-term seizure control with acceptable morbidity
and mortality risks. Englot et al. studied 1,226 patients with
supratentorial CM-related seizures and showed that 75% of
them became seizure-free upon CM resection. They also
identified that gross-total resection, surgery within the 1 year
of symptom onset, CM size less than 1.5 cm, and having a
single CM lesion are factors that significantly increase the rate
of successful seizure control [41]. Additionally, Sommer et
al. used intraoperative 1.5 TMRI (iopMRI) and neuronaviga-
tional software to surgically treat epilepsy in 26 patients.They
managed complete seizure control in 80.8% of their patients,
as observed during a 47.7-monthmean follow-up period [42].
Using iopMRI was significant in completely removing the
CM lesion in 23% of their patients, who would otherwise
have a low chance of being seizure-free [41, 43]. Nonetheless,
in spite of the promising data on the effectiveness of CM
resection in treating epilepsy, antiepileptic drugs should still
be the first-line treatment for CM-related epilepsy due to the
complication risks associated with surgery.
3.2. Brainstem Cavernomas (BSCMs). BSCMs make up
approximately 20–35% of all CMs and are deeply located in
the medulla, pons, and midbrain [1].The annual hemorrhage
risk (AHR) for spontaneous BSCMs has been shown to be
0.25–6.5% per patient-year, while the risk rises to 3.8–35%
if the patient has a history of prior hemorrhage [14, 44, 45].
Some studies report the AHR to range from 4.5% up to 60%
in patients with history of a prior hemorrhage [46]. Due to
their location, hemorrhages from BSCMs exert pressure on
the surrounding cranial nerve nuclei and tracts, leading to
neurological deficits in 60% of the patients [47]. The blood is
slowly absorbed and the symptoms often attenuate over time.
The resection of BSCM lesions entails a greater compli-
cation risk than resecting other CM lesions. This surgery
has been shown to often produce symptoms that resemble a
hemorrhage due to the increased pressure in the brainstem,
but the symptoms disappear in the majority of the patients.
Due to the increased complication risk, the main criteria for
selecting surgery are severe clinical presentation, including
hemorrhage, and location within 2mm from pial surface. In
case the lesion has severe clinical presentation but is deeply
seated, surgery is selected only if the lesion is large and
accessible [48, 49]. Frischer et al. resected BSCM lesions with
amedian volume of 2 cm3 when amicrosurgical corridor was
available [48].
There aremany studies that have examined the short- and
long-term effects of microsurgical resection on patients with
BSCM lesions. More specifically, Li et al. reported complete
resection of the CM lesion in 95% of the patients with 35.1%
of the patients’ condition worsening postoperatively [50].
After a mean 89.4-month follow-up period, only 10.3% of
the patients remained in worse condition than preoperatively
[50]. Frischer et al. achieved complete excision in 90% of
patients and showed that 50% of the patients with residual
lesions experienced additional hemorrhages, resulting in an
AHR of 8.8% postoperatively [48, 51]. A study by Garrett
and Spetzler on patients with BSCM lesions examined the
neurological status of 137 patients immediately after the
surgery and found that 72.3% of them had improved or
were identical to their preoperative baseline [46]. After a
mean follow-up period of 52 months, 89.2% of them had
returned to their normal routine. In the same study, 88% of
the patients who received surgery were the same or better
than preoperatively. However, 3.5% of the patients died from
a surgery-related cause. Additionally, 58% of their patients
acquired new deficits, and 12% of all the patients treated had
permanent deficits [46].
Surgical resection has been shown to be effective in treat-
ing BSCM lesions, yet some studies present more concerning
results. Abla et al. showed that 7.7% of patients who under-
went resection experienced a rehemorrhage postoperatively
and 36% acquired permanent neurological deficits, and the
surgery resolved some or all of the preoperative symptoms in
only 45% of the patients [44].This is illustrated by the change
in the average Glasgow Outcome Score (GOS), which was
4.4 on admission, decreased to 4.2 at discharge, but rose to
4.6 at follow-up [44]. Ferroli et al. found that 44% of their
patients acquired new neurological deficits postoperatively
and 66% of whom eventually returned to or improved from
the preoperative baseline, while the deficits were permanent
in the rest of the patients [52].
The exact location of the lesion in the brainstem and
the experience of the neurosurgeon are the key to limiting
the risk of complications and the postoperative emergence
of neurological deficits. A large variation in the findings of
different studies is observed, whichmay be due to the varying
number of patients in each study in addition to the variability
in the experience of the surgeon and the advancement of
technology.
4. Stereotactic Radiosurgery
While microsurgical resection is the standard treatment for
cavernomas, the risk of complication is not negligible when
treating deeply located, eloquent CMs.When the surgical risk
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Table 1: Efficacy of treatments for brainstem cavernous malformations (BSCMs).
Treatment Recurrence of hemorrhage Permanentneurological deficits
Radiation-induced
adverse effects
Microsurgical resection
0.4% [50]
7.7% [44]
8.8%∗ [48]
10.8% [5]
12% [46]
15% [52]
36% [44]
N/A
1st 2 years After 2 years
Stereotactic radiosurgery
7.06% [56]
8.2% [57]
8.22% [60]
10.8% [54]
14%∗∗ [16]
0.6% [48]
1% [54]
1.37% [60]
1.50% [56]
2.03% [56]
7.3% [17]
22.2% [56]
4.1% [61]
5% [57]
8.2% [56]
11.8% [60]
8%–18.4% [54]
∗Patients with residual lesions postoperatively.
∗∗This refers to the rate of hemorrhage within the first year after SRS.
is high, stereotactic radiosurgery (SRS) can be used to prevent
the natural progression of the lesion.
Several studies have suggested that SRS is a safe and
effective method for treating surgically inaccessible CMs [53]
(Table 1). Lunsford et al. studied patients with high-risk CM
lesions who received SRS treatment and showed that the
risk of hemorrhage decreased from 32.5% to 10.8% in the
first 2 years and to 1% after 2 years [54]. In the same study,
18.4% of the patients experienced adverse radiation effects;
however the percentage decreased to 8% in the more recent
patients as technology advanced [53, 54]. Lu et al. performed a
meta-analysis study that included 178 patients with brainstem
CMs and they showed a significant reduction in the AHR
post-SRS treatment. According to their findings, the relative
risk for hemorrhage was 0.161 (95% CI 0.052–0.493; 𝑃 =
0.001), while 11.8% of the patients acquired transient or
permanent neurological deficits [55]. Furthermore, Lee et
al. studied the effectiveness of gamma knife radiosurgery
(GKRS) on patients with brainstem cavernousmalformations
and showed that SRS should be considered as a treatment
for brainstem CMs even in patients with only one previous
hemorrhage [56]. The first study group consisted of patients
who received GKRS treatment after a single hemorrhagic
event, while the second study group had a history of 2 or
more CM hemorrhages. The first group had an AHR of
7.06% within the first 2 years, and 2.03% after two years
[56]. The second group had an AHR of 38.36% before
SRS, 9.82% within the first two years post-SRS, and 1.50%
after 2 years. However, 22.2% of the patients in the second
group experienced new or aggravated neurological deficits
from recurring hemorrhages [56]. In addition, Park and
Hwang studied 21 patients who had experienced at least one
hemorrhage due to their brainstem intra-axial CMs (1.55
hemorrhages per patient on average) [57]. They observed
patients for a median of 32 months and noted that the risk
of hemorrhage decreased from 39.5% to 8.2% after GKRS,
while only one patient (5%) experienced adverse radiation
effects. The risk of bleeding was reduced to 0% two years
postoperatively [57].
Despite the growing evidence supporting SRS for inoper-
able CMs, some of the aforementioned studies present sig-
nificant radiation-induced adverse effects and neurological
deficits, as summarized in Table 1. It is thus imperative to note
some limitations when studying the efficacy of SRS that may
affect the SRS-associated morbidity rate. Hemorrhages due
to cavernomas tend to occur in clusters with long intervals
without any hemorrhages (temporal clustering) [16]. Barker
II et al. showed that the incidence rate of a second hemor-
rhage within 1 year was 14%, but the cumulative incidence
increased to 56% after 5 years [16]. Hence, the decreased risk
of hemorrhage recurrence observed when following patients
for an average 32 months could be due to the hemorrhage-
free intervals seen in CM patients. Moreover, Poorthuis et
al. conducted a metaregression analysis on CMs treated by
SRS and showed that there is not any statistically significant
association between the risk factors of each patient and the
outcome of the procedure [58]. Their findings suggest that
there is a large variation in the findings of SRS studies and
that the long-term effects of SRS treatment still need to be
determined [58].
5. Conservative Management
Due to the potential risks associated with interventional
treatment, there have been several studies on the effective-
ness of medical management of CMs, allowing lesions to
progress naturally and only alleviating the clinical symptoms.
Ferna´ndez et al. reported that surgical treatment of CM
patients with nonrefractory epilepsy did not significantly
decrease the risk of future seizures when compared with
conservative management. They observed 17 patients who
received medical management for 5 years and 12 of them
(70.6%) remained seizure-free [59]. In contrast, other studies
report that CM patients that received conservative treatment
had a poorer outcome in the long term than patients who
received surgical intervention (42% versus 9% resp.) [12, 36].
Garrett and Spetzler studied 14 patients who were managed
conservatively and found that 50% of them improved or
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remained at their baseline, 29% became worse, and 7% died,
while 14% did not complete the study [46].
While some positive findings on conservative manage-
ment have been reported, there are important limitations to
these studies. First of all, the number of patients studied is
not large enough to represent the large range of cases seen in
the hospital. Additionally, these studies were not randomized
clinical trials, in which patients are randomly assigned to
either surgical or medical management. Instead, researchers
retrospectively studied patients who did not receive surgical
treatment for various reasons, for example, because they
maintained good control of their epilepsy, because of the
location of CM, or simply because they declined surgery.
However, this introduces bias to these studies, because it is
very likely that these patients had less symptomatic lesions
and therefore a milder and safer natural progression than the
average CM patient. In addition, observing patients for only
a few years is not sufficient, since the point of interventional
management is to eradicate the risk of developing any
permanent neurological deficits in the long term and prevent
the AHR from increasing with time.
6. Conclusion
Cerebral cavernomas are the most common vascular abnor-
mality, yet they are often undiagnosed. Using advanced
imaging techniques such as T2 ∗ GRE sequences, high-field
MR, and susceptibility-weighted imaging, we are now able
to detect all of the CM lesions present in the brain. With
the help of the intraoperative neuronavigational techniques,
diffusion-tensor and fMR imaging, neurosurgeons can resect
deep-seated lesions in eloquent areas of the brain with
minimal new neurological deficits and low mortality and
morbidity rates. Stereotactic radiosurgery has also advanced
significantly and can be used to effectively treat inoperable
cavernomas.More studies on SRS are needed though in order
to examine its long-term effects on the neurological status
of patients. Additionally, the natural history of cavernomas
needs to be investigated further for it is crucial when assessing
the efficacy of the methods of treatment.
Conflict of Interests
The authors declare no conflict of interests regarding the
findings presented in this paper.
References
[1] R. T. Dalyai, G. Ghobrial, I. Awad et al., “Management of inci-
dental cavernousmalformations: a review,”Neurosurgical Focus,
vol. 31, no. 6, article E5, 2011.
[2] S. Yadla, P. M. Jabbour, R. Shenkar, C. Shi, P. G. Campbell, and
I. A. Awad, “Cerebral cavernous malformations as a disease
of vascular permeability: from bench to bedside with caution,”
Neurosurgical focus, vol. 29, no. 3, p. E4, 2010.
[3] R. Raychaudhuri, H. H. Batjer, and I. A. Awad, “Intracranial
cavernous angioma: a practical review of clinical and biological
aspects,” Surgical Neurology, vol. 63, no. 4, pp. 319–328, 2005.
[4] V. A. D’Angelo, C. De Bonis, R. Amoroso et al., “Supratento-
rial cerebral cavernous malformations: clinical, surgical, and
genetic involvement,”Neurosurgical Focus, vol. 21, no. 1, 7 pages,
2006.
[5] C.-C. Wang, A. Liu, J.-T. Zhang, B. Sun, and Y.-L. Zhao, “Sur-
gical management of brain-stem cavernous malformations:
report of 137 cases,” Surgical Neurology, vol. 59, no. 6, pp. 444–
454, 2003.
[6] E. F. Hauck, S. L. Barnett, J. A. White, and D. Samson, “Symp-
tomatic brainstem cavernomas,”Neurosurgery, vol. 64, no. 1, pp.
61–71, 2009.
[7] P. G. Campbell, P. Jabbour, S. Yadla, and I. A. Awad, “Emerging
clinical imaging techniques for cerebral cavernous malforma-
tions: a systematic review,” Neurosurgical Focus, vol. 29, no. 3,
pp. 1–8, 2010.
[8] J. R. Robinson, I. A. Awad, and J. R. Little, “Natural history of
the cavernous angioma,” Journal of Neurosurgery, vol. 75, no. 5,
pp. 709–714, 1991.
[9] N. Chalouhi, A. S. Dumont, C. Randazzo et al., “Management
of incidentally discovered intracranial vascular abnormalities,”
Neurosurgical Focus, vol. 31, no. 6, p. E1, 2011.
[10] D. Kondziolka, L. D. Lunsford, and J. R. W. Kestle, “The
natural history of cerebral cavernous malformations,” Journal
of Neurosurgery, vol. 83, no. 5, pp. 820–824, 1995.
[11] P. J. Porter, R.A.Willinsky,W.Harper, andM.C.Wallace, “Cere-
bral cavernous malformations: natural history and prognosis
after clinical deteriorationwith orwithout hemorrhage,” Journal
of Neurosurgery, vol. 87, no. 2, pp. 190–197, 1997.
[12] R. W. Porter, P. W. Detwiler, R. F. Spetzler et al., “Cavernous
malformations of the brainstem: experience with 100 patients,”
Journal of Neurosurgery, vol. 90, no. 1, pp. 50–58, 1999.
[13] T. Aiba, R. Tanaka, T. Koike, S. Kameyama, N. Takeda, and T.
Komata, “Natural history of intracranial cavernous malforma-
tions,” Journal of Neurosurgery, vol. 83, no. 1, pp. 56–59, 1995.
[14] J. M. Zabramski, T. M. Wascher, R. F. Spetzler et al., “The
natural history of familial cavernous malformations: results of
an ongoing study,” Journal of Neurosurgery, vol. 80, no. 3, pp.
422–432, 1994.
[15] S. Laberge-le Couteulx, H. H. Jung, P. Labauge et al., “Trun-
cating mutations in CCM1, encoding KRIT1, cause hereditary
cavernous angiomas,” Nature Genetics, vol. 23, no. 2, pp. 189–
193, 1999.
[16] F. G. Barker II, S. Amin-Hanjani, W. E. Butler et al., “Temporal
clustering of hemorrhages fromuntreated cavernousmalforma-
tions of the central nervous system,” Neurosurgery, vol. 49, no.
1, pp. 15–25, 2001.
[17] T. Hasegawa, J. McInerney, D. Kondziolka et al., “Long-term
results after stereotactic radiosurgery for patients with cav-
ernous malformations,” Neurosurgery, vol. 50, no. 6, pp. 1190–
1198, 2002.
[18] P. P. Rivera, R. A. Willinsky, and P. J. Porter, “Intracranial cav-
ernousmalformations,”Neuroimaging Clinics of North America,
vol. 13, no. 1, pp. 27–40, 2003.
[19] K. A. Cauley, T. Andrews, J. V. Gonyea, and C. G. Filippi,
“Magnetic resonance diffusion tensor imaging and tractog-
raphy of intracranial cavernous malformations: preliminary
observations and characterization of the hemosiderin rim,”
Journal of Neurosurgery, vol. 112, no. 4, pp. 814–823, 2010.
[20] J. N. Maraire and I. A. Awad, “Intracranial cavernous malfor-
mations: lesion behavior and management strategies,” Neuro-
surgery, vol. 37, no. 4, pp. 591–605, 1995.
The Scientific World Journal 7
[21] P. Labauge, S. Laberge, L. Brunereau, C. Levy, and E. Tournier-
Lasserve, “Hereditary cerebral cavernous angiomas: clinical and
genetic features in 57 French families,”The Lancet, vol. 352, no.
9144, pp. 1892–1897, 1998.
[22] F.-G. Lehnhardt, U. von Smekal, B. Ru¨ckriem et al., “Value of
gradient-echo magnetic resonance-imaging in the diagnosis of
familial cerebral cavernous malformation,” Archives of Neurol-
ogy, vol. 62, no. 4, pp. 653–658, 2005.
[23] P. Dammann, M. Barth, Y. Zhu et al., “Susceptibility weighted
magnetic resonance imaging of cerebral cavernous malfor-
mations: prospects, drawbacks, and first experience at ultra-
high field strength (7-Tesla) magnetic resonance imaging,”
Neurosurgical Focus, vol. 29, no. 3, article E5, 2010.
[24] V. Novak, A. Chowdhary, A. Abduljalil, P. Novak, and D. Chak-
eres, “Venous cavernoma at 8 Tesla MRI,” Magnetic Resonance
Imaging, vol. 21, no. 9, pp. 1087–1089, 2003.
[25] M. Schlamann, S. Maderwald, W. Becker et al., “Cerebral cav-
ernous hemangiomas at 7 Tesla: initial experience,” Academic
Radiology, vol. 17, no. 1, pp. 3–6, 2010.
[26] J. M. De Souza, R. C. Domingues, L. C. H. Cruz Jr., F. S. Dom-
ingues, T. Iasbeck, and E. L. Gasparetto, “Susceptibility-
weighted imaging for the evaluation of patients with familial
cerebral cavernous malformations: a comparison with T2-
weighted fast spin-echo and gradient-echo sequences,” The
American Journal of Neuroradiology, vol. 29, no. 1, pp. 154–158,
2008.
[27] W. Lin, P. Mukherjee, H. An et al., “Improving high-resolution
MR bold venographic imaging using a T1 reducing contrast
agent,” Journal of Magnetic Resonance Imaging, vol. 10, no. 2, pp.
118–123, 1999.
[28] K. Niizuma, M. Fujimura, T. Kumabe, S. Higano, and T. Tom-
inaga, “Surgical treatment of paraventricular cavernous angi-
oma: fibre tracking for visualizing the corticospinal tract and
determining surgical approach,” Journal of Clinical Neuro-
science, vol. 13, no. 10, pp. 1028–1032, 2006.
[29] X. Chen, D. Weigel, O. Ganslandt, M. Buchfelder, and C. Nim-
sky, “Diffusion tensor imaging andwhitematter tractography in
patients with brainstem lesions,” Acta Neurochirurgica, vol. 149,
no. 11, pp. 1117–1131, 2007.
[30] X. Chen, D.Weigel, O. Ganslandt, R. Fahlbusch, M. Buchfelder,
and C. Nimsky, “Diffusion tensor-based fiber tracking and
intraoperative neuronavigation for the resection of a brainstem
cavernous angioma,” Surgical Neurology, vol. 68, no. 3, pp. 285–
291, 2007.
[31] M. J. Schlosser, G. McCarthy, R. K. Fulbright, J. C. Gore, and
I. A. Awad, “Cerebral vascular malformations adjacent to sen-
sorimotor and visual cortex: functional magnetic resonance
imaging studies before and after therapeutic intervention,”
Stroke, vol. 28, no. 6, pp. 1130–1137, 1997.
[32] G. W. Thickbroom, M. L. Byrnes, I. T. Morris, M. J. Fallon, N.
W. Knuckey, and F. L.Mastaglia, “FunctionalMRI near vascular
anomalies: comparison of cavernoma and arteriovenous mal-
formation,” Journal of Clinical Neuroscience, vol. 11, no. 8, pp.
845–848, 2004.
[33] D. Zotta, A. Di Rienzo, A. Scogna, A. Ricci, G. Ricci, and
R. J. Galzio, “Supratentorial cavernomas in eloquent brain
areas: Application of neuronavigation and functional MRI in
operative planning,” Journal of Neurosurgical Sciences, vol. 49,
no. 1, pp. 13–19, 2005.
[34] R. E. Clatterbuck, J. L. Moriarity, I. Elmaci, R. R. Lee, S. N.
Breiter, and D. Rigamonti, “Dynamic nature of cavernous mal-
formations: a prospective magnetic resonance imaging study
with volumetric analysis,” Journal of Neurosurgery, vol. 93, no.
6, pp. 981–986, 2000.
[35] G. K. Steinberg, S. D. Chang, R. J. Gewirtz, and J. R. Lopez,
“Microsurgical resection of brainstem, thalamic, and basal
ganglia angiographically occult vascular malformations,” Neu-
rosurgery, vol. 46, no. 2, pp. 260–271, 2000.
[36] O. Bozinov, T. Hatano, J. Sarnthein, J.-K. Burkhardt, and
H. Bertalanffy, “Current clinical management of brainstem
cavernomas,” Swiss Medical Weekly, vol. 140, p. w13120, 2010.
[37] M. Cenzato, R. Stefini, C. Ambrosi, and M. Giovanelli, “Post-
operative remnants of brainstem cavernomas: incidence, risk
factors and management,” Acta Neurochirurgica, vol. 150, no. 9,
pp. 879–886, 2008.
[38] S. Amin-Hanjani, C. S. Ogilvy, R. G. Ojemann, and R.M. Crow-
ell, “Risks of surgicalmanagement for cavernousmalformations
of the nervous system,” Neurosurgery, vol. 42, no. 6, pp. 1220–
1228, 1998.
[39] H. Bertalanffy, L. Benes, T. Miyazawa, O. Alberti, A. M. Siegel,
and U. Sure, “Cerebral cavernomas in the adult. Review of
the literature and analysis of 72 surgically treated patients,”
Neurosurgical Review, vol. 25, no. 1-2, pp. 1–53, 2002.
[40] J. Gralla, O. Ganslandt, H. Kober, M. Buchfelder, R. Fahlbusch,
and C. Nimsky, “Image-guided removal of supratentorial cav-
ernomas in critical brain areas: application of neuronavigation
and intraoperative magnetic resonance imaging,” Minimally
Invasive Neurosurgery, vol. 46, no. 2, pp. 72–77, 2003.
[41] D. J. Englot, S. J. Han,M. T. Lawton, and E. F. Chang, “Predictors
of seizure freedom in the surgical treatment of supratentorial
cavernous malformations,” Journal of Neurosurgery, vol. 115, no.
6, pp. 1169–1174, 2011.
[42] B. Sommer, B. S. Kasper, R. Coras et al., “Surgical management
of epilepsy due to cerebral cavernomas using neuronavigation
and intraoperative MR imaging,”Neurological Research, vol. 35,
no. 10, pp. 1076–1083, 2013.
[43] D.-S. Kim, Y.-G. Park, J.-U. Choi, S.-S. Chung, and K.-C. Lee,
“An analysis of the natural history of cavernousmalformations,”
Surgical Neurology, vol. 48, no. 1, pp. 9–18, 1997.
[44] A. A. Abla, G. P. Lekovic, J. D. Turner, J. G. deOliveira, R. Porter,
and R. F. Spetzler, “Advances in the treatment and outcome
of brainstem cavernous malformation surgery: a single-center
case series of 300 surgically treated patients,” Neurosurgery, vol.
68, no. 2, pp. 403–414, 2011.
[45] B. A. Gross, H. H. Batjer, I. A. Awad, and B. R. Bendok, “Brains-
tem cavernous malformations,”Neurosurgery, vol. 64, no. 5, pp.
E805–E818, 2009.
[46] M. Garrett and R. F. Spetzler, “Surgical treatment of brainstem
cavernousmalformations,” Surgical Neurology, vol. 72, no. 2, pp.
S3–S10, 2009.
[47] K. Mizoi, T. Yoshimoto, and J. Suzuki, “Clinical analysis of ten
cases with surgically treated brain stem cavernous angiomas,”
Tohoku Journal of Experimental Medicine, vol. 166, no. 2, pp.
259–267, 1992.
[48] J. M. Frischer, B. Gatterbauer, S. Holzer et al., “Microsurgery
and radiosurgery for brainstem cavernomas: effective and
complementary treatment options,”WorldNeurosurgery, vol. 81,
no. 3-4, pp. 520–528, 2014.
[49] A. A. Abla, J. D. Turner, A. P. Mitha, G. Lekovic, and R. F. Spetz-
ler, “Surgical approaches to brainstem cavernous malforma-
tions,” Neurosurgical Focus, vol. 29, no. 3, article E8, 2010.
[50] D. Li, Y. Yang, S.-Y. Hao et al., “Hemorrhage risk, surgical
management, and functional outcome of brainstem cavernous
8 The Scientific World Journal
malformations,” Journal of Neurosurgery, vol. 119, no. 4, pp. 996–
1008, 2013.
[51] B. A. Gross, H. H. Batjer, I. A. Awad, B. R. Bendok, and R. Du,
“Brainstem cavernous malformations: 1390 surgical cases from
the literature,” World Neurosurgery, vol. 80, no. 1-2, pp. 89–93,
2013.
[52] P. Ferroli, M. Sinisi, A. Franzini, S. Giombini, C. L. Solero, and
G. Broggi, “Brainstem cavernomas: long-term results of micro-
surgical resection in 52 patients,” Neurosurgery, vol. 56, no. 6,
pp. 1203–1212, 2005.
[53] N. Chalouhi, P. Jabbour, and D.W. Andrews, “Stereotactic radi-
osurgery for cavernous malformations: is it effective?” World
Neurosurgery, vol. 80, no. 6, pp. e185–e186, 2013.
[54] L. D. Lunsford, A. A. Khan, A. Niranjan, H. Kano, J. C. Flick-
inger, and D. Kondziolka, “Stereotactic radiosurgery for symp-
tomatic solitary cerebral cavernous malformations considered
high risk for resection,” Journal of Neurosurgery, vol. 113, no. 1,
pp. 23–29, 2010.
[55] X.-Y. Lu, H. Sun, J.-G. Xu, and Q.-Y. Li, “Stereotactic radio-
surgery of brainstem cavernous malformations: a systematic
review and meta-analysis: a review,” Journal of Neurosurgery,
vol. 120, no. 4, pp. 982–987, 2014.
[56] S. H. Lee, H. J. Choi, H. S. Shin, S. K. Choi, I. H. Oh, and Y.
J. Lim, “Gamma knife radiosurgery for brainstem cavernous
malformations: should a patient wait for the rebleed?” Acta
Neurochirurgica, 2014.
[57] S.-H. Park and S.-K. Hwang, “Gamma knife radiosurgery for
symptomatic brainstem intra-axial cavernous malformations,”
World Neurosurgery, vol. 80, no. 6, pp. e261–e266, 2013.
[58] M.H. F. Poorthuis, C. J.M. Klijn, A. Algra, G. J. E. Rinkel, and R.
Al-Shahi Salman, “Treatment of cerebral cavernous malforma-
tions: a systematic review andmeta-regression analysis,” Journal
of Neurology, Neurosurgery and Psychiatry, 2014.
[59] S. Ferna´ndez, J. Miro´, M. Falip et al., “Surgical versus conser-
vative treatment in patients with cerebral cavernomas and non
refractory epilepsy,” Seizure, vol. 21, no. 10, pp. 785–788, 2012.
[60] E.A.Monaco,A.A.Khan,A.Niranjan et al., “Stereotactic radio-
surgery for the treatment of symptomatic brainstem cavernous
malformations,” Neurosurgical focus, vol. 29, no. 3, p. E11, 2010.
[61] C.-C. Lee, D. H.-C. Pan, W.-Y. Chung et al., “Brainstem cav-
ernous malformations: the role of Gamma Knife surgery,”
Journal of Neurosurgery, vol. 117, pp. 164–169, 2012.
